Adicet Bio, Inc.
ACET · XNASCIK 1720580fmd_1S6HC2Y4DD708ZEA2N02DJRJ3JManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 02, 2016 to Sep 30, 2026, 40 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Research and development | 17 | 15 | 24 | 34 | 49 | 71 | 106 | 99 | 99 |
| Total operating expenses | 19 | 23 | 32 | 57 | 71 | 98 | 152 | 128 | 122 |
| Operating income | (19) | (15) | (31) | (39) | (61) | (73) | (152) | (128) | (122) |
| Interest expense | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | – | 1 | 1 | 1 | 0 | 4 | 10 | 11 | 6 |
| Other non-operating income (expense) | (15) | 5 | 2 | (1) | (1) | (1) | (1) | (0) | (0) |
| Income before taxes | (34) | (10) | (28) | (39) | (62) | (70) | (143) | (117) | (117) |
| Income tax expense | 0 | (1) | 0 | (3) | (0) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (34) | (9) | (28) | (37) | (62) | (70) | (143) | (117) | (117) |
| Net income | (34) | (9) | (28) | (37) | (62) | (70) | (143) | (117) | (117) |
| Net income to common shareholders | (34) | (9) | (28) | (37) | (62) | (70) | (143) | (117) | (117) |